Poly Medicure (531768) Q4 99/00 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 99/00 earnings summary
2 Nov, 2026Executive summary
FY2000 returned to profitability: net profit Rs 34.43 lakh versus a prior-year loss; gross revenue rose to Rs 1,048.76 lakh from Rs 650.29 lakh.
Production increased 77.10% YoY to 115.53 lakh medical disposables, with capacity utilization improving to 76.88% from 54.25%.
Financial highlights
Gross revenue Rs 1,048.76 lakh; total expenditure Rs 816.59 lakh; interest and finance charges Rs 103.49 lakh; PBT Rs 38.93 lakh.
Audited P&L reports net profit Rs 34.43 lakh versus prior-year loss Rs 5.01 lakh; tax provision was Rs 4.50 lakh.
Product sales, including trading goods, were Rs 1,036.66 lakh; other income Rs 12.10 lakh; inventory change was a Rs 10.19 lakh decrease.
Outlook and guidance
Management expected production and sales in FY2001 to exceed the prior year despite tough competition in domestic and export markets.
Following encouraging trade-fair response and CE Mark registration across the product range, higher export sales were expected in FY2001.
Latest events from Poly Medicure
- Acquisition-led revenue growth and a European rebound faced pressure on consolidated margins.531768
Q2 26/27 - Commercial production began in Apr 1997 after delays; FY turnover and PBT were nil.531768
Q4 96/97 - Revenue and production grew, but depreciation drove a FY99 net loss.531768
Q4 98/99 - First-period profit was modest as depressed markets and blood-bag restrictions curtailed performance.531768
Q4 97/98 - Higher production lifted profit, while commissioned expansion set up the next growth phase.531768
Q4 01/02 - FY04 growth and capacity expansion advanced, with exports at 83.8% of sales.531768
Q4 03/04 - Profit and exports surged as capacity expansion and Egypt production plans advanced.531768
Q4 02/03 - Record production and higher profit fuel expansion amid pricing and currency pressures.531768
Q4 05/06 - Sales rose 31.2%, PAT climbed 40.4%, and exports reached 86.4% of sales.531768
Q4 04/05